Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Immunogenicity, Relative Efficacy, Safety and Reactogenicity of Flublok Quadrivalent® (Quadrivalent Recombinant Influenza Vaccine, Seasonal Formulation) Compared With a Marketed Quadrivalent Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years-old.

NCT03460743 is registered in ClinicalTrials.gov with Laboratorios Liomont as lead sponsor.

NCT NCT03460743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03460743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Immunogenicity, Relative Efficacy, Safety and Reactogenicity of Flublok Quadrivalent® (Quadrivalent Recombinant Influenza Vaccine, Seasonal Formulation) Compared With a Marketed Quadrivalent Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years-old.
Lead sponsor
Laboratorios Liomont
Phase
Phase 3
Overall status
Completed
Start date
March 22, 2018
Completion date
October 22, 2019
Enrollment
1,556 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human